News & Publications

May 5, 2026 – The Society for Clinical Research Sites (SCRS) congratulates David Vulcano on his appointment as CEO of the Association of Clinical Research Professionals (ACRP).  […]

Four organizations share how they’ve meaningfully cut redundant site training burdens through role-based assignments, on-demand guidance, and intuitive design — all without compromising compliance. Their shared takeaway: training should enable performance, not create a paper trail.

Traditional budget models haven’t kept up with the realities of modern trial execution. Sites absorb hidden costs that sponsors don’t account for, leading to adversarial negotiations, delayed startups, and strained resources. Forward-thinking sponsors are changing that with technology fees, contingency funds, and a genuine effort to understand what sites actually need.

Most studies have support resources in place, but sites often don’t know what’s available or how to access it. When support stays invisible, manual workarounds take over and burden shifts back to already-stretched teams. Visible, easy-to-use support benefits sites and participants alike.

Mobile tools add real value for short, time-bound actions like approvals, sign-offs, and safety notifications — but mobility rarely means mobile-only. New efficiency gains come with new governance questions around auditability and accessibility. The biggest wins come when mobile design respects the realities of busy clinical environments.

Dropout rates of 30–40% are common in cardiometabolic trials, yet retention is still treated as a downstream problem rather than a design decision. The real drivers — visit burden, logistics, side effects — are predictable, which means they’re preventable. Until trials are designed around how participants actually live, the enrollment-to-completion gap will persist.

Digital tools are reshaping clinical trials, but they can’t eliminate every barrier patients face. Sites absorb the friction between protocol design and patient reality daily. Making trials truly accessible requires pairing technology with human-centered support.

Study delays, holds, and cancellations increased 105% in 2025 compared to 2024, representing one of the most significant operational challenges facing research sites today. These disruptions […]

In recent years, a concerning trend has emerged in the clinical research industry. Some sponsors and Contract Research Organizations (CROs) are attempting to extend site payments […]

This year’s SCRS Global Site Solutions Summit celebrated the people and organizations driving clinical research forward. From groundbreaking operational solutions to transformative leadership and measurable impact on patient outcomes, the award recipients represent the best of what collaboration, innovation, and commitment can achieve. These are the organizations and leaders setting the standard for what’s possible…

For over a decade, Cognizant’s Shared Investigator Platform (SIP) has transformed global clinical research, evolving from a bold vision into a trusted solution that connects thousands of sponsors, sites, and investigators. Today, SIP continues to streamline collaboration, accelerate trials, and enhance transparency to deliver better patient outcomes.

Clinical research continues to evolve toward greater connectivity and efficiency, yet study startup remains one of the most complex and time-consuming stages of a trial. Disjointed systems and communication gaps between sponsors, CROs, and research sites often lead to avoidable delays. To address these challenges, Advarra…

“It’s incredibly frustrating […] we want technology that actually improves their job”. This was shared in a recent Site Listening Session, but it’s a sentiment I’m sure many can relate to. When tools that are intended to support and accelerate are delivered without their users in mind, it’s a recipe for failure. For sites, every redundant training, missed integration opportunity, and feature that doesn’t quite work as it should, ticks away at the time that could be better spent with patients.

The landscape of oncology clinical research is rapidly evolving with the emergence of radiopharmaceutical therapies, also known as radioligand therapy (RLT). These innovative treatments represent a precision medicine approach that uses targeted radiation to treat cancer with a goal of minimizing damage to healthy tissue. However,

Direct-to-patient clinical trials are removing traditional barriers to research participation by bringing study activities into patients’ homes. Through partnerships that combine virtual site operations with global medication delivery, trials can now reach more diverse populations while reducing travel burdens and accelerating enrollment. Read on to learn how Science 37 and Catalent are making this possible.